BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8429682)

  • 1. Biodistribution and in vivo antitumor efficacy of the systemically administered anti-human T-leukemia immunotoxins and potentiation of their efficacy by alpha-interferon.
    Yokota S; Okazaki M; Yoshida M; Seon BK
    Leuk Res; 1993 Jan; 17(1):69-79. PubMed ID: 8429682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
    Yokota S; Hara H; Luo Y; Seon BK
    Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.
    Hara H; Seon BK
    Proc Natl Acad Sci U S A; 1987 May; 84(10):3390-4. PubMed ID: 3494997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
    Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
    J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM; Aberle S; Bernhard SL; Kung AH
    Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
    Luo Y; Seon BK
    J Immunol; 1990 Sep; 145(6):1974-82. PubMed ID: 1697314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
    Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
    Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
    Vallera DA; Uckun FM
    Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.
    van Oosterhout YV; Preijers FW; Wessels HM; de Witte T
    Cancer Res; 1992 Nov; 52(21):5921-5. PubMed ID: 1394218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.